5.01
1.38%
-0.07
After Hours:
5.01
Wave Life Sciences Ltd. stock is currently priced at $5.01, with a 24-hour trading volume of 421.95K.
It has seen a -1.38% decreased in the last 24 hours and a -13.17% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $5.07 pivot point. If it approaches the $4.96 support level, significant changes may occur.
Previous Close:
$5.08
Open:
$5.05
24h Volume:
421.95K
Market Cap:
$612.64M
Revenue:
$113.31M
Net Income/Loss:
$-57.51M
P/E Ratio:
-3.6838
EPS:
-1.36
Net Cash Flow:
$-20.55M
1W Performance:
+4.59%
1M Performance:
-13.17%
6M Performance:
-10.38%
1Y Performance:
+24.63%
Wave Life Sciences Ltd. Stock (WVE) Company Profile
Name
Wave Life Sciences Ltd.
Sector
Industry
Phone
-
Address
Marina One East Tower, No. 12-00, 7 Straits View, Singapore
Wave Life Sciences Ltd. Stock (WVE) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jul-05-23 | Initiated | Raymond James | Outperform |
May-24-23 | Downgrade | Jefferies | Buy → Hold |
Dec-15-20 | Resumed | H.C. Wainwright | Buy |
Oct-23-20 | Initiated | RBC Capital Mkts | Sector Perform |
Dec-31-19 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
Nov-01-19 | Initiated | Guggenheim | Buy |
Jul-15-19 | Initiated | Cowen | Market Perform |
Apr-17-19 | Reiterated | H.C. Wainwright | Buy |
Aug-07-18 | Initiated | Stifel | Buy |
Jul-23-18 | Initiated | H.C. Wainwright | Buy |
Mar-19-18 | Reiterated | Mizuho | Buy |
Feb-15-17 | Initiated | H.C. Wainwright | Buy |
Nov-10-16 | Resumed | Leerink Partners | Outperform |
Dec-07-15 | Initiated | JMP Securities | Mkt Outperform |
Dec-07-15 | Initiated | Jefferies | Buy |
Dec-07-15 | Initiated | Leerink Partners | Outperform |
Dec-07-15 | Initiated | Sun Trust Rbsn Humphrey | Buy |
View All
Wave Life Sciences Ltd. Stock (WVE) Latest News
Why HighPeak Energy Shares Are Trading Lower By 15%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Benzinga
Why United Natural Foods Shares Are Trading Lower By 15%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Benzinga
Box Reports Upbeat Earnings, Joins American Public Education, Wave Life Sciences And Other Big Stocks Moving Higher On Wednesday
Benzinga
Wave Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
GlobeNewswire Inc.
Wave Life Sciences Fourth Quarter and Full Year 2023 Financial Results Scheduled for March 6, 2024
GlobeNewswire Inc.
Wave Life Sciences (WVE) Surges 10.9%: Is This an Indication of Further Gains?
Zacks Investment Research
Wave Life Sciences Ltd. Stock (WVE) Financials Data
Wave Life Sciences Ltd. (WVE) Revenue 2024
WVE reported a revenue (TTM) of $113.31 million for the quarter ending December 31, 2023, a +3,005% rise year-over-year.
Wave Life Sciences Ltd. (WVE) Net Income 2024
WVE net income (TTM) was -$57.51 million for the quarter ending December 31, 2023, a +64.46% increase year-over-year.
Wave Life Sciences Ltd. (WVE) Cash Flow 2024
WVE recorded a free cash flow (TTM) of -$20.55 million for the quarter ending December 31, 2023, a +84.09% increase year-over-year.
Wave Life Sciences Ltd. (WVE) Earnings per Share 2024
WVE earnings per share (TTM) was -$0.55 for the quarter ending December 31, 2023, a +74.18% growth year-over-year.
About Wave Life Sciences Ltd.
Wave Life Sciences Ltd., a biotechnology company, designs, develops, and commercializes nucleic acid therapeutic candidates for genetically defined diseases by utilizing proprietary synthetic chemistry drug development platform. The company is primarily developing oligonucleotides that target genetic defects to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins. It focuses on proprietary programs in neurology in the central nervous system and neuromuscular system. The company has a research, license, and option agreement with Pfizer Inc. and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of stereopure oligonucleotide therapeutics and oligonucleotide therapeutics, as well as a collaboration agreement with Deep Genomics Inc. for identifying novel therapies. Wave Life Sciences Ltd. was founded in 2012 and is based in Singapore.
Cap:
|
Volume (24h):